Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.1413445112 http://scihub22266oqcxt.onion/10.1073/pnas.1413445112 C4291638!4291638!25535360     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2015 ; 112 (1): 94-9 Nephropedia Template TP {{tp|p=25535360|t=2015. Transdermal deferoxamine prevents pressure-induced diabetic ulcers |pdf=|usr=}}{{25535360}} gab.com Text Transdermal deferoxamine prevents pressure-induced diabetic ulcers JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=25535360 #FOAvip Diabetes is the leading cause of nontraumatic amputations. There are no effective therapies to prevent diabetic ulcer formation and only modestly effective technologies to help with their healing. To enhance diabetic wound healing we designed a transdermal delivery system containing the FDA-approved small molecule deferoxamine, an iron chelator that increases defective hypoxia inducible factor-1 alpha transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress. This system overcomes the challenge of delivering hydrophilic molecules through the normally impermeable stratum corneum and both prevents diabetic ulcer formation and improves the healing of existing diabetic wounds. This represents a prophylactic pharmacological agent to prevent ulcer formation that is rapidly translatable into the clinic and has the potential to ultimately transform the care and prevention of diabetic complications. Twit Text FOAVip Transdermal deferoxamine prevents pressure-induced diabetic ulcers ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=25535360 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25535360 #FOAvip English Wikipedia <ref>{{Cite pmid|25535360}}</ref> Transdermal deferoxamine prevents pressure-induced diabetic ulcers #MMPMID25535360 Duscher D; Neofytou E; Wong VW; Maan ZN; Rennert RC; Inayathullah M; Januszyk M; Rodrigues M; Malkovskiy AV; Whitmore AJ; Walmsley GG; Galvez MG; Whittam AJ; Brownlee M; Rajadas J; Gurtner GC Proc Natl Acad Sci U S A 2015[Jan]; 112 (1): 94-9 PMID25535360show ga Diabetes is the leading cause of nontraumatic amputations. There are no effective therapies to prevent diabetic ulcer formation and only modestly effective technologies to help with their healing. To enhance diabetic wound healing we designed a transdermal delivery system containing the FDA-approved small molecule deferoxamine, an iron chelator that increases defective hypoxia inducible factor-1 alpha transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress. This system overcomes the challenge of delivering hydrophilic molecules through the normally impermeable stratum corneum and both prevents diabetic ulcer formation and improves the healing of existing diabetic wounds. This represents a prophylactic pharmacological agent to prevent ulcer formation that is rapidly translatable into the clinic and has the potential to ultimately transform the care and prevention of diabetic complications. äTransdermal deferoxamine prevents pressure-induced diabetic ulcers (epmc).pdf DeepDyve Pubget Overpricing